Zobrazeno 1 - 10
of 189
pro vyhledávání: '"Moti L, Kashyap"'
Autor:
Melissa Soohoo, Hamid Moradi, Yoshitsugu Obi, Connie M. Rhee, Elvira O. Gosmanova, Miklos Z. Molnar, Moti L. Kashyap, Daniel L. Gillen, Csaba P. Kovesdy, Kamyar Kalantar‐Zadeh, Elani Streja
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 8, Iss 6 (2019)
Background Although studies have shown that statin therapy in patients with non–dialysis‐dependent chronic kidney disease was associated with a lower risk of death, this was not observed in dialysis patients newly initiated on statins. It is uncl
Externí odkaz:
https://doaj.org/article/492d7d458f5145dab67b7b0892ff82de
Autor:
Tae Ik Chang, Elani Streja, Gang Jee Ko, Neda Naderi, Connie M. Rhee, Csaba P. Kovesdy, Moti L. Kashyap, Nosratola D. Vaziri, Kamyar Kalantar‐Zadeh, Hamid Moradi
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 12 (2018)
Background There is accumulating evidence that serum levels of non–high‐density lipoprotein cholesterol (non–HDL‐C) are a more accurate predictor of cardiovascular outcomes when compared with low‐density lipoprotein cholesterol. However, we
Externí odkaz:
https://doaj.org/article/74f20bc155c24a3a82610364117e5de7
Publikováno v:
Journal of Lipid Research, Vol 53, Iss 5, Pp 941-950 (2012)
The lipidation of apoA-I in liver greatly influences HDL biogenesis and plasma HDL levels by stabilizing the secreted apoA-I. Niacin is the most effective lipid-regulating agent clinically available to raise HDL. This study was undertaken to identify
Externí odkaz:
https://doaj.org/article/93e8fb8fc5c34ba38680dc2a67097473
Publikováno v:
Journal of Lipid Research, Vol 51, Iss 8, Pp 2211-2222 (2010)
Pioglitazone, a hypoglycemic agent, has been shown to increase plasma HDL cholesterol, but the mechanism is incompletely understood. We further investigated effects of pioglitazone on transcriptional regulation of apolipoprotein (apo)A-I gene and fun
Externí odkaz:
https://doaj.org/article/2e1a662a4fc24e7c90b3b353e4a079fd
Publikováno v:
Journal of Lipid Research, Vol 49, Iss 6, Pp 1195-1201 (2008)
Niacin is an effective agent for raising HDL, but its cellular target sites are largely unknown. We examined effects of niacin on the surface expression of ATP synthase β chain, a newly described HDL/apolipoprotein A-I (apoA-I) receptor for HDL endo
Externí odkaz:
https://doaj.org/article/03da20afc7c34848a97763e00288b5bd
Autor:
Shobha H. Ganji, S. Tavintharan, Daming Zhu, Yiding Xing, Vaijinath S. Kamanna, Moti L. Kashyap
Publikováno v:
Journal of Lipid Research, Vol 45, Iss 10, Pp 1835-1845 (2004)
Niacin is a widely used lipid-regulating agent in dyslipidemic patients. Previously, we have shown that niacin inhibits triacylglycerol synthesis. In this report, using HepG2 cells, we have examined the effect of niacin on the mRNA expression and mic
Externí odkaz:
https://doaj.org/article/dd0ffdc4d8c34c1da895b7e8d2e6fae6
Publikováno v:
Journal of Clinical Lipidology. 13:873-879
Niacin has been widely used clinically for over half a century for dyslipidemia. Recent new evidence indicates that niacin may be useful in the treatment of nonalcoholic fatty liver disease (NAFLD) and its sequential complications including nonalcoho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a00bbb663c6e339f8af0aba10561f9b
https://doi.org/10.1016/j.jacl.2019.10.006
https://doi.org/10.1016/j.jacl.2019.10.006
Autor:
Melissa Soohoo, Connie M. Rhee, Elani Streja, Christina Park, Moti L. Kashyap, Donovan A Argueta, Nicholas V. DiPatrizio, Nosratola D. Vaziri, Daniele Piomelli, Miki Igarashi, Hamid Moradi, Kamyar Kalantar-Zadeh, Amy S. You, Jennifer Daglian
Publikováno v:
Journal of the Endocrine Society
Journal of the Endocrine Society, vol 3, iss 10
Journal of the Endocrine Society, vol 3, iss 10
Context Previous studies have shown that the endocannabinoid system plays a major role in energy metabolism through the actions of its main mediators, 2-arachidonoyl-sn-glycerol (2-AG) and anandamide (AEA). Objective We examined serum levels of major
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81cb5722e90932803b23541c6f63bc78
http://europepmc.org/articles/PMC6767629
http://europepmc.org/articles/PMC6767629
Autor:
Jerome L. Fleg, Patrice Desvigne-Nickens, William E. Boden, Yao Yao, Santica M. Marcovina, Alexandru Topliceanu, John J. Albers, Todd Anderson, Mark E. McGovern, Radmila Lyubarova, Ruth McBride, Moti L. Kashyap
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 24:534-541
Background: Lipoprotein-associated phospholipase A2 (LpPLA2) is an inflammatory marker that has been associated with the presence of vulnerable plaque and increased risk of cardiovascular (CV) events. Objective: To assess the effect of extended-relea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54f410ebe2ae6533e9522216d22d8aaa
https://doi.org/10.1177/1074248419852955
https://doi.org/10.1177/1074248419852955
Publikováno v:
Archives of Gastroenterology Research. 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::23e7834d9694eae5be0e1724054bf652
https://doi.org/10.33696/gastroenterology.1.015
https://doi.org/10.33696/gastroenterology.1.015